How to alleviate ravages of the disease without bankrupting individuals or Medicare program?
The Food and Drug Administration recently granted fast-track approval to a new Alzheimer’s drug designed to slow the rate of cognitive decline for individuals in the early stages of the disease.
Leqembi is now available on the market. But without Medicare or private insurance, only the wealthy will be able to afford the cost of $26,500 per year. They will have to balance the cost against slowing the progression of the disease by 3-5 months. Because the trial ran for 18 months, it’s too early to tell whether Leqembi has any long-term benefits.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Analysis of Cellular “Vehicles” Sheds New Light on Alzheimer’s, Parkinson’s, and ALSScientists at Oregon State University have made a key advancement in understanding neurodegenerative diseases by utilizing various biophysical techniques to gain insight into a motor protein that plays a crucial role in many disorders. The study, which was published in the journal eLife, represen
Read more »
Rutgers will open a new Alzheimer’s and dementia clinic this yearThe new Rutgers clinic will focus on developing new treatments for people with Alzheimer's and other forms of dementia.
Read more »
'End the Scam': Democrats Unveil Bill to Change Name of Medicare Advantage'Only Medicare is Medicare,' said Rep. Mark Pocan. 'These non-Medicare plans run by private insurers undermine traditional Medicare.'
Read more »
Tomlinson: GOP would slash Medicare and MedicaidU.S. taxpayers spend more on health care than citizens of any other wealthy country but...
Read more »
No Amount of Fraud Deters Government Agencies When It Comes to Privatizing MedicareSadly, getting the fraudsters out of ACO REACH will not improve a program designed to enrich corporations and harm patients. This entire apple cart needs to be overturned.
Read more »
Health-insurance stocks drop after Medicare Advantage proposes lower rates for 2024Humana's stock was down 3.3% in trading on Thursday, while shares of UnitedHealth Group, Elevance Health and Cigna Corp. also fell.
Read more »